Dr. Nathwani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-301-8116
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2009 - 2010- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2008 - 2009
- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2007 - 2008
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2004 - 2007
Topiwala National Medical CollegeClass of 2002
Certifications & Licensure
CA State Medical License 2006 - 2026
AK State Medical License 2023 - 2024- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Start of enrollment: 2017 Sep 05
- Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Roles: Contact
Publications & Presentations
PubMed
- A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2025-01-01 - A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory mult...Hang Quach, Gurdeep Parmar, Enrique M Ocio, H Miles Prince, Albert Oriol
Haematologica. 2024-12-01 - An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multi...Prashant Kapoor, Nitya Nathwani, Tomas Jelinek, Ludek Pour, Aurore Perrot
European Journal of Haematology. 2024-11-01
Abstracts/Posters
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Nitya Nathwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary ResultsNitya Nathwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...Nitya Nathwani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
